Gossamer Bio
GOSS
98 hedge funds and large institutions have $192M invested in Gossamer Bio in 2023 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 33 increasing their positions, 22 reducing their positions, and 19 closing their positions.
239% more call options, than puts
Call options by funds: $3.18M | Put options by funds: $936K
50% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 22
16% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 19
12% more capital invested
Capital invested by funds: $171M → $192M (+$20.8M)
3% more funds holding
Funds holding: 95 → 98 (+3)
1.6% more ownership
Funds ownership: 91.22% → 92.82% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.59M |
| 2 |
AG
Artal Group
Luxembourg
|
+$4.18M |
| 3 |
Morgan Stanley
New York
|
+$3.82M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.81M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$5.41M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.19M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$4M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.87M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.78M |
GOSS Hedge Fund Activity: Q4 2023 in Review
98 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q4 2023, worth a combined $192M — up 12% from $171M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new GOSS positions and 19 closed out — a net gain of 3 holders — while 33 added to existing stakes and 22 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $8.59M. The largest seller was Boxer Capital, exiting entirely with an estimated $5.41M sold.
- 98 institutional investors held Gossamer Bio (GOSS) as of Q4 2023, up from 95 in Q3 2023.
- Funds reported $192M of Gossamer Bio stock for Q4 2023, up 12% quarter-over-quarter.
- 22 funds opened new Gossamer Bio positions in Q4 2023 and 19 closed out, a net change of +3 holders.
- The largest Gossamer Bio buyer in Q4 2023 was Fidelity Investments, an estimated $8.59M added.
- The largest Gossamer Bio seller in Q4 2023 was Boxer Capital, an estimated $5.41M sold.
Based on aggregated 13F filings for Q4 2023.